Arcutis Biotherapeutics, Inc. Common Stock
Here’s whether Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: 50-day MA is rising (+3.27% over 10 days); RSI 44 — healthy momentum range; strong 1-year return of +58.8%; 3-month momentum positive (+20.2%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative). Currently 21.1% off its 52-week high. Score: +1/7.
ARQT is trading below its 200-day MA ($25.61) — a key warning sign the longer-term trend is under pressure. An RSI of 44.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +58.8% compares to +20.5% for SPY (beat the market by 38.4%). The current 21.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.